Repligen Yönetim

Tazminat ve Piyasa: Olivier 'nin toplam tazminatı ($USD 5.45M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın altındadır ($USD 7.88M ).

Tazminat ve Kazançlar: Olivier şirketinin tazminatını şirket performansıyla karşılaştırmak için yeterli veri yok.

CEO

Olivier Loeillot (54 yo)

1.1yrs

Görev süresi

US$5,445,065

Tazminat

Mr. Olivier Loeillot is President of Repligen Corporation from October 02, 2023 & served as it's Chief Commercial Officer and serves as it's CEO & Director since September 1, 2024. Mr. Loeillot served a co...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Anthony Hunt	Executive Chair	9.5yrs	US$7.93m	0.18% $ 14.3m
Olivier Loeillot	President	1.1yrs	US$5.45m	Veri yok
Jason Garland	CFO & Chief Compliance Officer	1.2yrs	US$2.03m	Veri yok
James Bylund	Chief Operating Officer	4.7yrs	US$3.74m	0.0075% $ 592.6k
Ralf Kuriyel	Senior Vice President of Research & Development	8.1yrs	US$1.66m	0.010% $ 808.5k
Keith Robinson	Chief Information Officer	no data	Veri yok	Veri yok
Sondra Newman	Global Head of Investor Relations	no data	Veri yok	Veri yok
Kimberly Cornwell	Global Head of Legal	no data	Veri yok	Veri yok
Neil Whitfield	VP & Global Head of Sales	2.1yrs	Veri yok	Veri yok
Leslie Galvin	Vice President of Human Resources	1.8yrs	Veri yok	Veri yok
Kola Otitoju	Senior VP of Strategy and Business Development & Global Head of Bioprocess Analytics	4.8yrs	Veri yok	Veri yok
Dianne Heiler	Senior Director of Packaging & Sustainability	no data	Veri yok	Veri yok

2.0yrs

Ortalama Görev Süresi

60yo

Ortalama Yaş

Deneyimli Yönetim: RGEN 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 2 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Anthony Hunt	Executive Chair	9.5yrs	US$7.93m	0.18% $ 14.3m
Olivier Loeillot	President	less than a year	US$5.45m	Veri yok
Glenn Muir	Independent Director	9.1yrs	US$322.84k	0.022% $ 1.8m
Charles Leland Cooney	Member of Scientific Advisory Board	8.7yrs	Veri yok	Veri yok
Martin Madaus	Independent Director	1.8yrs	US$453.50k	0.0070% $ 551.6k
Karen Dawes	Lead Independent Director	19.2yrs	US$431.12k	0.16% $ 12.7m
J. Love	Member of Scientific Advisory Board	8.7yrs	Veri yok	Veri yok
Konstantin Konstantinov	Member of Scientific Advisory Board & Independent Director	8.7yrs	US$282.84k	0.00095% $ 74.9k
Steven Cramer	Member of Scientific Advisory Board	8.7yrs	Veri yok	Veri yok
Rohin Mhatre	Independent Director	4.7yrs	US$287.84k	0.0042% $ 330.2k
Richard Braatz	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Nicholas Barthelemy	Independent Director	10.4yrs	US$307.84k	0.0071% $ 557.9k

8.7yrs

Ortalama Görev Süresi

64yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: RGEN 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 8.7 yıldır).

Repligen Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Executive Chair recently sold US$1.8m worth of stock

Executive Chair notifies of intention to sell stock

Insufficient new directors

Insider notifies of intention to sell stock

Insider recently sold US$740k worth of stock

Repligen Corporation Announces CEO Changes, Effective September 1, 2024

Recent updates

Repligen Corporation's Earnings Preview: Expensive With Mixed Growth Prospects

Repligen (NASDAQ:RGEN) Has A Pretty Healthy Balance Sheet

Repligen Corporation to Report Q3, 2024 Results on Nov 12, 2024

Is It Time To Consider Buying Repligen Corporation (NASDAQ:RGEN)?

Executive Chair recently sold US$1.8m worth of stock

Executive Chair notifies of intention to sell stock

Repligen Corporation's (NASDAQ:RGEN) Intrinsic Value Is Potentially 28% Above Its Share Price

Insufficient new directors

Now 25% undervalued after recent price drop

Now 22% undervalued after recent price drop

Insider notifies of intention to sell stock

Insider recently sold US$740k worth of stock

Repligen Corporation Provides Earnings Guidance for the Fiscal Year 2024

Second quarter 2024 earnings: EPS misses analyst expectations

Repligen Corporation (NASDAQ:RGEN) Stocks Shoot Up 27% But Its P/S Still Looks Reasonable

Repligen Corporation (NasdaqGS:RGEN) entered into a definitive agreement to acquire Tantti Laboratory Inc.

Now 20% undervalued after recent price drop

Repligen Corporation to Report Q2, 2024 Results on Jul 30, 2024

We Think Repligen (NASDAQ:RGEN) Can Stay On Top Of Its Debt

Repligen: Strong Filtration Growth, Offset By Other Challenges

Now 28% undervalued after recent price drop

Now 20% undervalued after recent price drop

Repligen Corporation Announces CEO Changes, Effective September 1, 2024

Repligen Corporation Announces Management Changes, Effective September 1, 2024

Why We're Not Concerned Yet About Repligen Corporation's (NASDAQ:RGEN) 27% Share Price Plunge

Is Now The Time To Look At Buying Repligen Corporation (NASDAQ:RGEN)?

Now 20% undervalued after recent price drop

Ecolab Life Sciences and Repligen Announce the Commercial Launch of DurA Cycle Affinity Resin for Large-Scale Biologic Manufacturing

Repligen Stock: Still Quite Overvalued

CEO & Director recently sold US$3.4m worth of stock

CEO & Director notifies of intention to sell stock

Consensus EPS estimates increase by 10%

Repligen Corporation Just Missed Earnings - But Analysts Have Updated Their Models

Repligen Corporation Provides Earnings Guidance for the Fiscal Year 2024

New minor risk - Earnings quality

First quarter 2024 earnings: EPS misses analyst expectations

Estimating The Intrinsic Value Of Repligen Corporation (NASDAQ:RGEN)

Repligen Corporation to Report Q1, 2024 Results on May 01, 2024

Repligen (NASDAQ:RGEN) Has A Pretty Healthy Balance Sheet

Repligen Corporation, Annual General Meeting, May 16, 2024

Repligen Corporation Appoints Maggie A. Pax as Board of Directors

CEO & Director recently sold US$3.3m worth of stock

CEO & Director notifies of intention to sell stock

Consensus EPS estimates fall by 45%

Chief Operating Officer recently sold US$680k worth of stock

Chief Operating Officer notifies of intention to sell stock

Price target increased by 8.2% to US$205

Repligen Corporation Provides Earnings Guidance for the Year 2024

At US$206, Is Repligen Corporation (NASDAQ:RGEN) Worth Looking At Closely?

Repligen Corporation to Report Q4, 2023 Results on Feb 21, 2024

Estimating The Intrinsic Value Of Repligen Corporation (NASDAQ:RGEN)

Why We're Not Concerned About Repligen Corporation's (NASDAQ:RGEN) Share Price

Repligen Corporation announced that it has received $290.1 million in funding

Repligen Corporation announced that it expects to receive $290.1 million in funding

Repligen Corporation announced that it expects to receive $290.1 million in funding

Insider recently sold US$557k worth of stock

Consensus EPS estimates increase by 16%

Repligen Corporation Launches TangenX®? SC as First-To-Market Holder-Free Self-Contained TFF Device

Price target decreased by 7.6% to US$179

Repligen Corporation Provides Earnings Guidance for the Fiscal Year 2023

What Does Repligen Corporation's (NASDAQ:RGEN) Share Price Indicate?

Third quarter 2023 earnings: EPS exceeds analyst expectations

Investor sentiment deteriorates as stock falls 16%

Repligen Corporation to Report Q3, 2023 Results on Oct 31, 2023

Is Repligen (NASDAQ:RGEN) Using Too Much Debt?

Repligen Corporation Appoints Olivier Loeillot as President and Chief Commercial Officer

Is There An Opportunity With Repligen Corporation's (NASDAQ:RGEN) 22% Undervaluation?

Repligen Corporation (NasdaqGS:RGEN) entered into a definitive agreement to acquire Metenova AB.

Now 23% undervalued